Harrow(us:HROW)

26.60

+1.49%

Updated on 2025-03-31

Open:25.52
Close:26.60
High:26.75
Low:24.78
Prev Close:26.21
Volume:796021.00
Turnover:20.75M
Turnover Ratio:2.23%
Shares:35.65M
MarketCap:948.40M
DateTotalTotal SharesTotal RatioNewIncreasedDecreased
2024-06-301271899134453.53%204149
2024-03-311222061664058.27%163651
2023-12-311352278380064.78%113963
2023-09-301342489822170.90%245137
2023-06-301412296587075.85%273265
2023-03-311262101219569.91%323245
2022-12-311021729122057.83%243130
2022-09-30931528653556.46%62736
dateorgNametotalratiochangeShareschangeRatio
2024-03-31Opaleye Management Inc.392060011.08%1006002.63%
2024-03-31Private Capital Management, Llc30123938.51%2178967.80%
2024-03-31Blackrock Inc.21827586.17%-37780-1.70%
2024-03-31Vanguard Group Inc18298055.17%212531.18%
2024-03-31Morgan Stanley9525232.69%-414218-30.31%
2024-03-31Geode Capital Management, Llc6939791.96%224333.34%
2024-03-31State Street Corp6353721.80%173322.80%
2024-03-31Stifel Financial Corp5207901.47%8881720.56%
2024-03-31Deutsche Bank Ag\5010161.42%-247839-33.10%
2024-03-31Renaissance Technologies Llc4773581.35%-133822-21.90%

About

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Address:102 Woodmont Boulevard,Suite 610

Market Movers